BioSpace News Archive

Salarius Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering, with total gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius.

Supernus Pharmaceuticals, Inc. announced that the Company expects to report business results for the fourth quarter and full year of 2019 after 5:00 p.m. ET on Tuesday, February 25, 2020.

TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced the addition of two key executives to its leadership team.

Beam Therapeutics Inc. announced the pricing of its initial public offering of 10,588,236 shares of common stock at a public offering price of $17.00 per share.

Eli Lilly Canada announced that Health Canada approved TALTZ® on February 4, 2020, for the treatment of adult patients with active ankylosing spondylitis, which is also known as radiographic axial spondyloarthritis, who have responded inadequately to, or are intolerant to, conventional therapy.

LHC Group, Inc. announced details for the release of its results for the fourth quarter and year ended December 31, 2019.

Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today that the U.S. Food and Drug Administration (FDA) has granted a De Novo classification order for its Surfacer® Inside-Out® Access Catheter System.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that Dr. Brian Poligone, clinical investigator and lead enroller in the pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study evaluating SGX301 in the treatment of early stage cutaneous T-cell lymphoma

ZYUS Life Sciences Inc. (“ZYUS”), a company focused on the global development and commercialization of innovative cannabinoid-based formulations, announced that it has received both its Analytical Testing Licence and Research Licence from Health Canada in accordance with Canada’s Cannabis Act and Cannabis Regulations

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), today announced positive topline results from two pivotal Phase 3 clinical trials for an ultra-potent topical corticosteroid product being developed for the treatment of plaque psoriasis using the Company’s patented Multiplexed Molecular Penetration Enhancer (“MMPE™") technology.